FDA Grants Fast Track to CytomX’s Varseta-M in Relapsed Metastatic Colorectal Cancer
FDA grants Fast Track to CytomX’s Varseta-M for relapsed metastatic colorectal cancer as a 2027 pivotal trial and new combinations approach.
/ 2 items
FDA grants Fast Track to CytomX’s Varseta-M for relapsed metastatic colorectal cancer as a 2027 pivotal trial and new combinations approach.
Shares of CytomX Therapeutics surged after strong Phase 1 trial data for Varsetatug Masetecan showed tumor shrinkage in late-stage colorectal cancer patients with mostly mild side effects.